Cargando…

Vincristine-Cyclophosphamide Combination Therapy Positively Affects T-Cell Subset Distribution in Systemic Lupus Erythematosus Patients

BACKGROUND: This study aimed to analyze the T-cell subset distribution in systemic lupus erythematosus (SLE) patients and determine whether vincristine-cyclophosphamide combination therapy can positively affect their T-cell subset distribution to keep the disease in remission. MATERIAL/METHODS: Thir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Junwei, Ding, Lijuan, Meng, Wu, Yang, Jinhua, Yan, Chenglan, Xie, Jianfang, Jing, Luo, Li, Xiaofeng, Fu, Zili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2015
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335592/ https://www.ncbi.nlm.nih.gov/pubmed/25683262 http://dx.doi.org/10.12659/MSM.893271

Ejemplares similares

The Role of γδ T Cells in Systemic Lupus Erythematosus
por: Wu, Meng, et al.
Publicado: (2016)

Immunoregulation of NKT Cells in Systemic Lupus Erythematosus
por: Chen, Junwei, et al.
Publicado: (2015)

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.
por: Sleijfer, S., et al.
Publicado: (1996)

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus
por: Katsuyama, Takayuki, et al.
Publicado: (2018)

Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus
por: Wolf, Victoria L., et al.
Publicado: (2019)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol
por: Miyachi, Mitsuru, et al.
Publicado: (2019)

Circulating T(FH) Subset Distribution Is Strongly Affected in Lupus Patients with an Active Disease
por: Le Coz, Carole, et al.
Publicado: (2013)

Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
por: Shimizu, Kazuyuki, et al.
Publicado: (1990)

Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis
por: Hirose, Sachiko, et al.
Publicado: (2019)

Two Cases of Refractory Thrombocytopenia in Systemic Lupus Erythematosus that Responded to Intravenous Low-Dose Cyclophosphamide
por: Park, Hee-Jin, et al.
Publicado: (2013)

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide
por: Lehman, Thomas JA, et al.
Publicado: (2014)

Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus
por: Fassbinder, Till, et al.
Publicado: (2015)

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus
por: Cheng, Hao, et al.
Publicado: (2022)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Successful Response to Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy in a Patient with Metastatic Carotid Body Paraganglioma
por: Yamada, Hiroki, et al.
Publicado: (2021)

Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections
por: Lu, Zhimin, et al.
Publicado: (2019)

Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus
por: Jin, Xin, et al.
Publicado: (2022)

Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosus
por: Baxter, Ryan M., et al.
Publicado: (2023)

Primary osteosarcoma of the urinary bladder following cyclophosphamide therapy for systemic lupus erythematosus: a case report
por: Baydar, Dilek Ertoy, et al.
Publicado: (2009)

Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: A case report
por: Chen, Jiali, et al.
Publicado: (2020)

Cyclophosphamide-induced seizures in a patient with neuropsychiatric systemic lupus erythematosus (NPSLE): A case report
por: Zhang, Lingshu, et al.
Publicado: (2023)

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
por: Berruti, A, et al.
Publicado: (1999)

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
por: Cebon, J. S., et al.
Publicado: (1990)

Combination Chemotherapy with Cyclophosphamide, Vincristine, Cisplatin and Etoposide(COPE) Combined with Radiotherapy for Small Cell Lung Cancer
por: Nam, Yong Jin, et al.
Publicado: (1995)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021)

Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus
por: Koarada, Syuichi, et al.
Publicado: (2012)

The expression of CXCR4/CXCL12 determines subsets of patients in systemic lupus erythematosus
por: Guilpain, Philippe, et al.
Publicado: (2011)

Pathogenesis of Renal Disease in Systemic Lupus Erythematosus—The Role of Autoantibodies and Lymphocytes Subset Abnormalities
por: Yap, Desmond Y. H., et al.
Publicado: (2015)

A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus
por: Hanaoka, Hironari, et al.
Publicado: (2020)

Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus: A pilot study
por: Qin, Ling, et al.
Publicado: (2019)

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004)

Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy
por: Matsukawa, Toshihiro, et al.
Publicado: (2018)

Paradoxical risk of reduced fertility after exposure of prepubertal mice to vincristine or cyclophosphamide at low gonadotoxic doses in humans
por: Delessard, Marion, et al.
Publicado: (2020)

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
por: Hojo, Nobumasa, et al.
Publicado: (2022)

Increased Tim-3 expression on peripheral T lymphocyte subsets and association with higher disease activity in systemic lupus erythematosus
por: Song, Li-jun, et al.
Publicado: (2015)

The Potential Role of Ferroptosis in Systemic Lupus Erythematosus
por: Chen, Qian, et al.
Publicado: (2022)

Mycophenolate versus Cyclophosphamide for Lupus Nephritis
por: Sahay, M., et al.
Publicado: (2018)

Revisited Cyclophosphamide in the Treatment of Lupus Nephritis
por: Quan, Xiao-ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eon5lqsodt5cesi11bb3e4v730